MAC Clinical Research

A full-service UK Contract Research Organisation (CRO) based in Manchester, MAC Clinical Research made history as the first company in the UK to administer high-dose ibogaine in a clinical environment, as well as the first to dose 50mg psilocybin and deuterated DMT. The firm serves as the CRO for DemeRx and atai Life Sciences’ MHRA-approved Phase I/IIa trial of ibogaine HCl (DMX-1002) for opioid use disorder, conducted at their Manchester Early Phase Unit.